Mythos Turns Model Release Into a Federal Vetting Question

The structural consequence of an FDA-style pre-release review regime is not about Mythos specifically — it is about who holds the release decision for every frontier model that follows. National security hawks inside the Trump administration now have a named incident and a named capability concern (cybersecurity and biological warfare potential) to justify a framework that previously had no domestic political constituency in this administration. Lawfare's analysis of the Mythos fallout notes the administration is weighing stricter oversight while cautioning against inflexible rules — but the flexibility argument cuts both…